FDA Approves First Once-Weekly Basal Insulin for Type 2 Diabetes

For decades, the mathematical reality of basal insulin therapy has been unyielding: 365 injections a year, administered one every single day without fail. For adults managing type 2 diabetes, that relentless schedule has often been a significant psychological and physical barrier to starting or maintaining necessary treatment. Now, the arithmetic of diabetes care is fundamentally changing. The U.S. Food and Drug Administration has officially approved Awiqli (insulin icodec-abae), the first once-weekly basal insulin for adults with type 2 diabetes, marking a major milestone in endocrinology.[1][2]

The approval represents one of the most significant shifts in insulin delivery since the introduction of the first 24-hour basal analogs more than two decades ago. By reducing the baseline injection burden from seven times a week to just one, the new therapy aims to remove the daily friction that causes many patients to delay initiating insulin therapy or to skip doses. Adherence to daily medication is notoriously difficult across all chronic diseases, but the addition of a needle makes insulin particularly challenging for many individuals.[6][7]

"It’s helping to reframe what basal insulin care can look like," said Dr. Anna Windle, a clinical development executive at Novo Nordisk, the drug's manufacturer, following the FDA's decision. For the millions of Americans whose type 2 diabetes is no longer adequately controlled by oral medications, diet, or exercise alone, the psychological hurdle of daily injections is a well-documented clinical challenge. Physicians frequently encounter "psychological insulin resistance," where patients will endure years of poorly controlled blood sugar simply to avoid the daily needle.[6][7]

To understand why a weekly insulin is considered a breakthrough, it helps to understand the specific role of basal insulin in the body. Unlike "mealtime" or bolus insulin—which is taken specifically to handle the sudden, sharp spike in glucose immediately after eating—basal insulin acts as the body's background regulator. It works quietly behind the scenes, keeping blood sugar levels stable overnight while sleeping and during the long stretches between meals, ensuring the liver doesn't release excess glucose into the bloodstream.[1][5]

Historically, extending the active life of injected insulin has been a complex biochemical puzzle. The earliest animal-derived insulins lasted only a few hours, requiring multiple shots a day just to survive. In the 1930s and 1940s, scientists added proteins like protamine to stretch the duration to a full day. By the year 2000, synthetic analogs like insulin glargine achieved a smoother, true 24-hour release profile. But breaking the 24-hour barrier to create a multi-day insulin required a completely different molecular architecture.[4]

Insulin icodec achieves its unprecedented seven-day lifespan through a clever biological mechanism: it effectively hijacks the body's own internal transport system. The insulin molecule was engineered with a specific structural modification that allows it to bind tightly to albumin, which is the most abundant protein found in human blood plasma. This binding process is the key to transforming a fast-acting hormone into a slow-drip reservoir that can sustain a patient for an entire week without requiring top-ups.[5]

When a patient injects the weekly dose, the insulin icodec molecules immediately attach to circulating albumin, creating an inactive "depot" in the bloodstream. Because the insulin is bound to the larger protein, it cannot interact with cellular receptors to lower blood sugar right away. Instead, it is slowly and continuously released from the albumin over the course of a week. This creates a steady, evenly distributed glucose-lowering effect that mimics the constant background insulin secretion of a healthy pancreas.[1][5]

The FDA's decision to approve the drug was anchored by the ONWARDS phase 3a clinical trial program, a massive global undertaking that enrolled roughly 2,680 adults with uncontrolled type 2 diabetes. The trials were designed to pit the new once-weekly injection directly against the current gold standard of care: daily basal insulins, including widely used medications like glargine and degludec. Researchers needed to prove that the convenience of a weekly shot did not come at the cost of diminished blood sugar control.[3][6]

The results of the ONWARDS trials were definitive and highly anticipated by the endocrinology community. Across the studies, patients using insulin icodec achieved reductions in hemoglobin A1C—the standard clinical measure of long-term blood sugar control over a two-to-three-month period—that were comparable, and in some specific trial measures superior, to those using daily injections. The data confirmed that the slow-release albumin depot was just as effective at managing chronic hyperglycemia as the daily routine it was designed to replace, validating the novel delivery mechanism.[1][7]

Beyond the primary blood test results, the trials also utilized continuous glucose monitors to measure "Time in Range"—the percentage of the day a patient's blood sugar stays within the healthy target zone of 70 to 180 mg/dL. The continuous monitoring data showed that the weekly injection kept patients in range just as effectively as the daily shots. This is a crucial metric, as maximizing time in range is directly correlated with preventing long-term diabetic complications like neuropathy, kidney disease, and vision loss.[2]

However, the transition to a weekly dose is not without its clinical complexities, and it requires a shift in how patients and doctors approach dosing. Because the drug stays active in the system for a full week, adjusting the dose requires more patience than with daily insulin. If a patient's blood sugar is running high, a doctor cannot simply instruct them to increase the dose the very next day; they must wait for the next weekly injection cycle to make a safe adjustment.[4]

Initiating the drug also requires a specific, carefully managed protocol. When a patient switches from a daily basal insulin to the weekly formulation, their first dose of Awiqli must be 1.5 times their expected weekly maintenance dose. This "loading dose" is biologically necessary to quickly build up the albumin-bound depot in the bloodstream. Without this larger initial dose, the patient would experience a dangerous gap in insulin coverage during the first week while the depot slowly establishes itself.[4]

The most closely watched safety metric in the trials was hypoglycemia, or dangerously low blood sugar. Because a weekly insulin cannot be quickly withdrawn from the body if blood sugar drops, regulators heavily scrutinized the data for severe events. If a patient takes too much daily insulin, the crisis usually resolves within hours; if a patient takes too much weekly insulin, the threat of low blood sugar could theoretically persist for days, requiring prolonged medical intervention and careful carbohydrate monitoring.[2][7]

In the type 2 diabetes trials, the risk of severe hypoglycemia was found to be very low. While there was a slight numerical increase in mild hypoglycemic events among those taking the weekly injection compared to daily insulin, the overall safety profile was deemed consistent with the broader basal insulin class. The FDA concluded that for adults with type 2 diabetes, the benefits of a weekly injection far outweighed the slight increase in mild low blood sugar events, provided patients are educated on the symptoms.[2][3][7]

The story is decidedly different for patients with type 1 diabetes. While regulatory agencies in Canada, Switzerland, and the European Union have approved insulin icodec for both type 1 and type 2 diabetes, the FDA explicitly rejected the drug for type 1 patients in the United States. This divergence highlights the differing risk tolerances between international health agencies when evaluating the unique vulnerabilities of the type 1 population, who rely entirely on exogenous insulin for survival and are highly sensitive to dosing miscalculations.[2][7]

In a trial comparing the weekly insulin to daily degludec in type 1 patients, the FDA concluded that the increased rate of hypoglycemic events outweighed the convenience of a weekly dose. People with type 1 diabetes produce absolutely no insulin of their own and are generally much more sensitive to insulin dosing errors. For these patients, the long-acting nature of a weekly depot was deemed too risky by U.S. regulators, as a miscalculated dose could lead to a prolonged and difficult-to-manage hypoglycemic emergency.[2][7]

For the type 2 population, however, the approval represents a tangible, immediate quality-of-life improvement. The drug is administered via a prefilled FlexTouch pen, and can be taken on the same day each week, with or without food. This flexibility is expected to be particularly beneficial for older adults who may rely on visiting nurses or family members to administer their injections, reducing the need for daily medical visits and allowing for greater independence in managing their chronic condition.[6][7]

The availability of a weekly option is also expected to change how primary care physicians approach diabetes management from the very beginning. Often, doctors and patients engage in a prolonged dance of "psychological insulin resistance," delaying the start of injection therapy for years while trying increasingly complex combinations of less effective oral medications. A once-a-week commitment is expected to be a much easier conversation in the clinic, potentially getting reluctant patients onto necessary insulin therapy much sooner and preventing years of cumulative organ damage.[2]

As the drug rolls out to pharmacies nationwide, the clinical focus will shift heavily toward patient education and safety protocols. Ensuring that patients do not accidentally take the weekly dose on a daily basis out of sheer habit, and teaching them how to safely manage the initial transition period, will be critical to the drug's real-world success outside of controlled trial environments. Pharmacists and certified diabetes care and education specialists will play a central role in ensuring the math of the new dosing schedule is clearly understood.[2][4]

Ultimately, the arrival of a weekly basal insulin is a testament to the steady, iterative progress of metabolic science over the past century. It does not cure diabetes, nor does it eliminate the need for careful dietary management, regular exercise, and consistent blood sugar monitoring. But it fundamentally reshapes the daily reality of living with the disease, giving millions of patients back a measure of freedom from the needle and offering a significantly simpler path to protecting their long-term health and well-being.[6]